Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV 16/18 E6/E7-encoding lentiviral vector-based vaccine Lenti-HPV-07

A cancer vaccine consisting of a non-integrative lentiviral vector encoding the detoxified forms of the human papillomavirus (HPV) subtypes 16 and 18 viral oncoproteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration, HPV 16/18 E6/E7-encoding lentiviral vector-based vaccine Lenti-HPV-07 may elicit a specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HPV 16/18 E6 and E7 oncoproteins, resulting in tumor cell lysis. HPV infections and HPV oncoproteins play a key role in the development of cervical and other cancers, including oropharyngeal and anogenital cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HPV 16/18 E6/E7-encoding lentiviral vector-based therapeutic vaccine Lenti-HPV-07
HPV therapeutic vaccine Lenti-HPV-07
lentiviral vector-encoding HPV16/18 E6/E7 Lenti-HPV-07
Code name:Lenti-HPV 07
Lenti-HPV-07
Lenti-HPV07
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search